Investors

Corporate Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Download Corporate Presentation
Corporate Presentation June 2025
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable U.S. securities law and forward-looking information within the meaning of applicable Canadian securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this presentation and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with:total revenue; net product sales; the timing, design and results of clinical studies; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this presentation apply only as of the date made and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.caor the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website atwww.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.
Changing the Trajectory of Autoimmune Diseases. (1) Continue LUPKYNIS commercial growth (2) Advance artinercept AUR200 development.
Lupkynis is the first FDA-approved oral therapy for treating lupus nephritis. A bar chart shows increasing net product sales from 2021 to 2025
About Lupus Nephritis
Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease. Over 200,000 people in the U.S. have SLE, and 20–60% develop LN. A graphic highlights that LN affects up to 120,000 people in the U.S. It explains that LN occurs when the immune system attacks the kidneys, disproportionately affects women and people of color, and causes protein in the urine, which is used to monitor disease and treatment. Inflammation can lead to impaired kidney function or failure.
Bar chart titled “LN Class by Proteinuria in Patients with SLE” shows that proteinuria is a significant risk factor for kidney damage. Among patients with proteinuria less than 0.5 g/day, 89.1% had severe LN class (III, IV, or V), while among those with ≥0.5 g/day, 99.4% had severe LN class. Only 10.9% and 0% had class II, respectively. Caption: Nearly 90% of patients with proteinuria <0.5 g/day have class III, IV, or V on biopsy.
Line graph shows that even a single flare of lupus nephritis (LN) can reduce kidney lifespan. The red line shows gradual decline in kidney function (GFR) with aging. The blue line shows faster decline after a single LN episode, and the purple line shows the steepest decline with ongoing LN. By age 100, the red line reaches CKD stage 3, while the blue and purple lines progress to stage 5. Caption: Nephron and podocyte loss lead to kidney damage as measured by GFR and proteinuria.
Line graph titled “Kidney Survival Based on Proteinuria Response Status” shows that greater proteinuria reduction is linked to long-term renal protection. At 10 years, kidney survival was 94% for patients with a complete response, 45% for partial response, and 19% for no response. The graph shows that better proteinuria response leads to higher kidney survival over time.
Lupkynis is a calcineurin-inhibitor immunosuppressant indicated for use with background immunosuppressive therapy to treat adult patients with active lupus nephritis.
Lupkynis is a novel, structurally modified calcineurin inhibitor (CNI) that targets lupus nephritis with a dual mechanism of action: (1) Immunosuppression—acts by inhibiting T-cell activation and cytokine production, and (2) Podocyte stability—promotes podocyte stability to reduce proteinuria. Presented under a banner labeled “Targeted Dual Mechanism of Action.”
Lupkynis has a robust clinical study history with three trials: AURA-LV (Phase 2, 265 patients), AURORA 1 (Phase 3, 357 patients), and AURORA 2 (Extension, 216 patients). A circular graphic highlights three key benefits of Lupkynis: Improved complete renal response rate, rapid proteinuria reduction, and established safety profile.
Bar graphs from the AURORA 1 study show that significantly more patients on Lupkynis achieved a complete renal response (CRR) compared to placebo. At week 52, 40.8% of patients on Lupkynis + MMF + corticosteroids achieved CRR vs. 22.5% on placebo + MMF + corticosteroids, making Lupkynis patients 81% more likely to achieve CRR. At week 24, 32.4% on Lupkynis achieved CRR vs. 19.7% on placebo, a 64% improvement.
Slide titled “LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1.” Two bar graphs show that patients receiving LUPKYNIS plus MMF and corticosteroids experienced faster reductions in proteinuria than those on placebo. Left graph: Median time to UPCR ≤0.5 mg/mg was 169 days for LUPKYNIS vs. 372 days for placebo — a 203-day improvement. Right graph: Median time to 50% UPCR reduction was 29 days for LUPKYNIS vs. 63 days for placebo — a 34-day improvement. Conclusion: LUPKYNIS cut proteinuria in half the time compared to standard treatment alone.
Table shows adverse reactions that occurred in ≥3% of patients treated with Lupkynis 23.7 mg twice daily and ≥2% more often than placebo in AURORA 1 and AURA-LV trials. Top adverse events for Lupkynis included decreased glomerular filtration rate (26%), hypertension (19%), diarrhea (19%), and headache (15%). Placebo group showed lower rates for most events. A note states that AURORA 2 confirmed Lupkynis had no unexpected safety signals over 3 years.
New American College of Rheumatology (ACR) Guideline Support Earlier Usage of LUPKYNIS.
The 2024 ACR Guideline for treating lupus nephritis recommends triple immunosuppressive therapy, including a calcineurin inhibitor (CNI) as first-line. Goals include reducing proteinuria to ≤0.5 mg/mg within 6–12 months and reducing corticosteroid use to ≤5 mg/day by 6 months. Lupkynis is the only FDA-approved CNI for LN. It achieved median proteinuria reduction to target in under 6 months, and 81% of patients were on ≤2.5 mg/day of steroids by week 16.
Aritinercept (AUR200) – A dual BAFF/APRIL inhibitor for the potential treatment of autoimmune diseases.
Slide explains that Aritinercept is a dual BAFF/APRIL inhibitor. It contains a BCMA-engineered extracellular domain with superior affinity for BAFF and APRIL, unlike others that use TACI. BCMA has stronger natural affinity for APRIL. Aritinercept also includes an IgG4 Fc domain with minimal immune activation, making it less inflammatory than IgG1-based therapies. An illustration on the right shows aritinercept binding to BAFF and APRIL with labeled components.
Slide titled “Role of BAFF and APRIL” explains that these cytokines regulate B cell survival and differentiation at various development stages. Targeting both BAFF and APRIL with aritinercept may prevent autoreactive B cell activation and reduce antibody levels. A diagram below shows B cell maturation from stem cells to plasma cells and memory B cells, highlighting stages dependent on BAFF and APRIL.
Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor. A table compares the binding affinity (Kd, in pM) of Aritinercept, Atacicept, and Telitacicept to BAFF and APRIL. Conclusion: Aritinercept has the highest affinity among the compared inhibitors.
Graphs and data table show that Aritinercept potently inhibits B cell proliferation driven by BAFF and APRIL. In dose-response curves, Aritinercept shows stronger suppression compared to Atacicept and Telitacicept. Aritinercept’s IC₅₀ is 0.02 nM for BAFF and 0.37 nM for APRIL. Compared to Aritinercept, Atacicept is 19x less potent for BAFF and 5.8x for APRIL; Telitacicept is 52.5x and 11.2x less potent. Caption: Aritinercept potently inhibits both BAFF- and APRIL-mediated B cell proliferation versus competitor inhibitors.
Aritinercept Reduced Immunoglobulins in Non-Human Primates
Aritinercept Single Ascending Dose (SAD) Study: Design
Aritinercept SAD Study:Safety Summary •Aritinercept was well tolerated at all dose levels tested •No treatment-related Grade ≥3 adverse events a •No treatment-related serious adverse events (SAEs) a •No discontinuations due to treatment-related adverse events •Adverse events that occurred in more than one subject included: –Injection site reactions b(24% aritinercept, 13% placebo) oAll injection site reactions were Grade 1
Aritinercept SAD Study: Pharmacokinetics Summary A half-life of 6-8 days after a single dose in the target dose range was observed
Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins in Humans Pharmacodynamic effects are supportive of once-monthly dosing
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG
Aritinercept SAD Study: Summary and Next Steps •Aritinercept was well tolerated at all dose levels tested •Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins supportive of once-monthly dosing •Aurinia plans to initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of 2025
Financial Overview
2024 Financial Highlights As of December 31, 2024, Aurinia had cash, cash equivalents, restricted cash and short-term investments of $358.5 million and zero debt.
2025 Financial Guidance Total revenue in 2024 was $235.1 million. 2025 guidance is $250.0M (up 6%) to $260.0M (up 11%). Net product sales in 2024 were $216.2 million. 2025 guidance is $240.0M (up 11%) to $250.0M (up 16%).
Aurinia Pharmaceuticals Inc. 2025. All rights reserved.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.

Stock Information

NASDAQ Global Market: AUPH

$8.68

+0.045

/

+0.52%

1,144,222

Volume

Last update:
Jun 30, 2025 1:30 PM ET
Pricing delayed by 15 minutes

Upcoming Events

There are no upcoming events scheduled at this time.

Past Events

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 6
-
May 6, 2021
May 6, 2021 5:00 PM
EDT
2021

First Quarter 2021 Financial Results Conference Call

Press Release10-QWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Apr 20
-
Apr 20, 2021
Apr 20, 2021 2:30 PM
EDT
2021

2021 Bloom Burton & Co. Healthcare Investor Conference

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Mar 17
-
Mar 17, 2021
Mar 17, 2021 10:40 AM
EDT
2021

Oppenheimer’s 31st Annual Healthcare Conference

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Mar 9
-
Mar 9, 2021
Mar 9, 2021 1:00 PM
EDT
2021

Scott Gottlieb, M.D. Hosts a Panel on Reimbursement and Pricing – Pre- and Post-Commercialization Considerations

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Mar 9
-
Mar 10, 2021
Mar 9, 2021 12:00 AM
2021

Fireside chat at H.C. Wainwright

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
No Results Found
Please try different keywords or filters.

SEC Filings

Select Year
Form Types
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Date
Filing Type
Description
Download
Date
December 9, 2024
2024
Filing Type
4
Description
Statement of Changes in Beneficial Ownership
Section 16 Filings
Download
Date
November 25, 2024
2024
Filing Type
4
Description
Statement of Changes in Beneficial Ownership
Section 16 Filings
Download
Date
November 25, 2024
2024
Filing Type
4
Description
Statement of Changes in Beneficial Ownership
Section 16 Filings
Download
Date
November 25, 2024
2024
Filing Type
4
Description
Statement of Changes in Beneficial Ownership
Section 16 Filings
Download
Date
November 25, 2024
2024
Filing Type
4
Description
Statement of Changes in Beneficial Ownership
Section 16 Filings
Download
No Results Found
Please try different keywords or filters.

Governance

Committee Charter Documents
Audit Committee Charter
Download
Compensation Committee Charter
Download
Corporate Governance Committee Charter
Download
Disclosure Committee Charter
Download
Governance Documents
Anti-Fraud Policy
Code of Ethics and Conduct
Articles
Certificate and Articles of Amendment
Certificate of Amalgamation
Conformed By-Law No. 2
Corporate Disclosure Policy
Forced Labour Report
Indemnity Policy
Insider Trading Policy
Majority Voting Policy
Mandate of the Board of Directors
Position Description - CFO
Position Description - President - CEO
Terms of Reference - Chairman
Whistleblower Policy

IR Contact

General inquiries can be sent to ir@auriniapharma.com